secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001193125-24-064353
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO prices upsized public offering of common stock and pre-funded warrants at $23.00 per share
--------------------------------------------------------------------------------

- Offering includes 4,565,260 shares at $23.00 and 1,521,740 pre-funded warrants at $22.9999, with gross proceeds ~$140M.
- Net proceeds expected ~$131.2M (or $150.9M if underwriters fully exercise 30-day option for 913,050 additional shares).
- Underwriters include Morgan Stanley, Goldman Sachs, Barclays, and Stifel as joint book-running managers.
- Pre-funded warrants have $0.0001 exercise price, are exercisable immediately, and do not expire.
- Offering expected to close March 11, 2024, under shelf registration statement (File No. 333-269086).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524064353/0001193125-24-064353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524064353/d795828d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-064353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer